Better Medicines, Better Life 2025 Full-Year Earnings Conference March 2026 1 Disclaimer This presentation has been prepared by Everest Medicines Limited (the "Company" and together with its subsidiaries, the "Group") solely for information purposes and does not constitute a recommendation regarding the securities of the Group or an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Group in any jurisdiction or an inducement to enter into investment activity, nor may ...

Financial Performance & Outlook - The company reported revenue of RMB 446 million, a 48% year-over-year increase, primarily driven by NEFECON® and XERAVA®[10, 12] - Gross margin was 76.4%, excluding amortization of intangible assets, reflecting NRDL price reduction of NEFECON® in mainland China and product cost optimization[10, 13] - Non-IFRS net loss decreased by 31% year-over-year to RMB 147 million[10] - The company expects full-year revenue to be between RMB 1.6 billion and RMB 1.8 billion, with NEFECON® revenue projected at RMB 1.2 billion to RMB 1.4 billion[10] - The company anticipates achieving operational profitability in the second half of 2025[9, 11] Key Products & Commercialization - NEFECON® revenue reached RMB 825 million from January to August 2025, with full NRDL coverage achieved in target provinces[8, 20] - NEFECON® is projected to generate RMB 1.2 billion to RMB 1.4 billion in revenue for the full year 2025 and RMB 2.4 billion to RMB 2.6 billion in 2026[10, 25] - XERAVA® generated RMB 143 million in revenue in the first half of 2025, a 6% year-over-year increase, with in-market sales up by 37%[32] - VELSIPITY® demonstrated a 51.9% mucosal healing rate with one year of treatment and is estimated to reach peak sales exceeding RMB 5 billion[49, 52] R&D Pipeline & Investments - EVER001 (Civorebrutinib) showed rapid and deep reductions in both Anti-PLA2R and 24h Proteinuria with an excellent safety profile[67] - The company completed a share placement on August 1, 2025, with net proceeds of HKD 1.6 billion[8, 10] - The company increased its strategic investment in I-MAB, becoming its single largest shareholder with 16.1% ownership[8, 116]